- Published on
KembaraXtra-Medicine- Acute Bronchitis
Acute bronchitis is a self-limited inflammatory condition of the trachea and bronchi, most commonly referred to as a “chest cold.” It is characterized by transient inflammation of the lower airways and typically follows an upper respiratory tract infection. The condition usually resolves on its own without long-term sequelae.
Acute bronchitis is common, particularly during the winter months, and occurs most frequently in smokers, older adults, and young children. In the United States, cough accounts for nearly 30 million ambulatory visits each year, with more than 12 million resulting in a diagnosis of bronchitis. Acute lower respiratory tract infection remains the most common condition treated in primary care settings.
Clinically, acute bronchitis often begins with symptoms typical of a common cold, such as nasal congestion and sore throat, followed by the development of cough. The cough is usually worse in the morning and may be productive, largely due to transient bronchial hyperresponsiveness. Patients may also experience low-grade fever, substernal discomfort that worsens with coughing, postnasal drip, and pharyngeal erythema. On auscultation, rhonchi that clear with coughing and occasional wheezing may be present. Illness severity varies depending on host factors such as age, immune status, smoking history, and underlying medical conditions. While mild cases resolve within 7 to 10 days, cough may persist for up to 3 weeks or longer in some individuals.
The most common cause of acute bronchitis is viral infection. Frequently implicated viruses include rhinovirus, influenza virus, adenovirus, respiratory syncytial virus, parainfluenza virus, coronavirus, and human metapneumovirus. Less commonly, atypical organisms such as Mycoplasma pneumoniae and Chlamydia pneumoniae may be responsible. Bacterial causes are uncommon but include Bordetella pertussis, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
The diagnosis of acute bronchitis is primarily clinical. Important conditions to consider in the differential diagnosis include pneumonia, asthma, sinusitis, bronchiolitis, influenza, gastroesophageal reflux disease, congestive heart failure (particularly in older adults), medication-induced cough, and bronchogenic neoplasm. Diagnostic testing is seldom necessary unless there is concern for pneumonia, influenza, or another serious underlying condition.
Routine laboratory testing is generally not required. Chest radiography is reserved for patients with suspected pneumonia, those with chronic obstructive pulmonary disease who fail to improve, or individuals with concerning features such as high fever, hypoxia, or focal lung findings.
Management of acute bronchitis is largely supportive. Nonpharmacologic measures include avoidance of tobacco smoke and other pulmonary irritants, increased fluid intake, and the use of vaporizers or humidifiers to improve airway comfort. Treatment focuses on symptom relief rather than eradication of infection.
Pharmacologic therapy is aimed at controlling cough and wheezing. Inhaled bronchodilators such as albuterol may be used for 1 to 2 weeks in patients with wheezing or significant cough and have been shown to reduce cough duration in adults with uncomplicated disease. Cough suppressants such as dextromethorphan and expectorants like guaifenesin are commonly recommended. Codeine may be considered for severe cough that significantly disrupts sleep.
Antibiotics are generally not indicated for acute bronchitis and should be reserved for select cases, such as patients with suspected pertussis, confirmed atypical bacterial infection, or those with COPD exacerbations accompanied by increased dyspnea and purulent sputum. Despite evidence showing minimal benefit, antibiotics are prescribed in 70% to 90% of visits for acute bronchitis, contributing to antibiotic resistance and increased adverse effects, particularly gastrointestinal symptoms. Clinical trials have consistently demonstrated no meaningful difference in outcomes between antibiotic and placebo therapy in uncomplicated cases.
The prognosis for acute bronchitis is excellent. Most patients recover fully within 7 to 10 days, though cough commonly persists for 10 to 14 days after presentation. Patients should be reassured about the expected course of illness and advised to seek further evaluation if symptoms worsen or fail to improve.
Referral for pulmonary function testing is generally unnecessary and should be considered only in patients with recurrent episodes of bronchitis or suspected underlying chronic pulmonary disease. Patient education is essential, emphasizing that acute bronchitis is usually viral, antibiotics are unlikely to help, and symptomatic management is the cornerstone of care.
Acute bronchitis is a self-limited inflammatory condition of the trachea and bronchi, most commonly referred to as a “chest cold.” It is characterized by transient inflammation of the lower airways and typically follows an upper respiratory tract infection. The condition usually resolves on its own without long-term sequelae.
Acute bronchitis is common, particularly during the winter months, and occurs most frequently in smokers, older adults, and young children. In the United States, cough accounts for nearly 30 million ambulatory visits each year, with more than 12 million resulting in a diagnosis of bronchitis. Acute lower respiratory tract infection remains the most common condition treated in primary care settings.
Clinically, acute bronchitis often begins with symptoms typical of a common cold, such as nasal congestion and sore throat, followed by the development of cough. The cough is usually worse in the morning and may be productive, largely due to transient bronchial hyperresponsiveness. Patients may also experience low-grade fever, substernal discomfort that worsens with coughing, postnasal drip, and pharyngeal erythema. On auscultation, rhonchi that clear with coughing and occasional wheezing may be present. Illness severity varies depending on host factors such as age, immune status, smoking history, and underlying medical conditions. While mild cases resolve within 7 to 10 days, cough may persist for up to 3 weeks or longer in some individuals.
The most common cause of acute bronchitis is viral infection. Frequently implicated viruses include rhinovirus, influenza virus, adenovirus, respiratory syncytial virus, parainfluenza virus, coronavirus, and human metapneumovirus. Less commonly, atypical organisms such as Mycoplasma pneumoniae and Chlamydia pneumoniae may be responsible. Bacterial causes are uncommon but include Bordetella pertussis, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
The diagnosis of acute bronchitis is primarily clinical. Important conditions to consider in the differential diagnosis include pneumonia, asthma, sinusitis, bronchiolitis, influenza, gastroesophageal reflux disease, congestive heart failure (particularly in older adults), medication-induced cough, and bronchogenic neoplasm. Diagnostic testing is seldom necessary unless there is concern for pneumonia, influenza, or another serious underlying condition.
Routine laboratory testing is generally not required. Chest radiography is reserved for patients with suspected pneumonia, those with chronic obstructive pulmonary disease who fail to improve, or individuals with concerning features such as high fever, hypoxia, or focal lung findings.
Management of acute bronchitis is largely supportive. Nonpharmacologic measures include avoidance of tobacco smoke and other pulmonary irritants, increased fluid intake, and the use of vaporizers or humidifiers to improve airway comfort. Treatment focuses on symptom relief rather than eradication of infection.
Pharmacologic therapy is aimed at controlling cough and wheezing. Inhaled bronchodilators such as albuterol may be used for 1 to 2 weeks in patients with wheezing or significant cough and have been shown to reduce cough duration in adults with uncomplicated disease. Cough suppressants such as dextromethorphan and expectorants like guaifenesin are commonly recommended. Codeine may be considered for severe cough that significantly disrupts sleep.
Antibiotics are generally not indicated for acute bronchitis and should be reserved for select cases, such as patients with suspected pertussis, confirmed atypical bacterial infection, or those with COPD exacerbations accompanied by increased dyspnea and purulent sputum. Despite evidence showing minimal benefit, antibiotics are prescribed in 70% to 90% of visits for acute bronchitis, contributing to antibiotic resistance and increased adverse effects, particularly gastrointestinal symptoms. Clinical trials have consistently demonstrated no meaningful difference in outcomes between antibiotic and placebo therapy in uncomplicated cases.
The prognosis for acute bronchitis is excellent. Most patients recover fully within 7 to 10 days, though cough commonly persists for 10 to 14 days after presentation. Patients should be reassured about the expected course of illness and advised to seek further evaluation if symptoms worsen or fail to improve.
Referral for pulmonary function testing is generally unnecessary and should be considered only in patients with recurrent episodes of bronchitis or suspected underlying chronic pulmonary disease. Patient education is essential, emphasizing that acute bronchitis is usually viral, antibiotics are unlikely to help, and symptomatic management is the cornerstone of care.
0 Comments
